Patents by Inventor John G. Flanagan
John G. Flanagan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220400943Abstract: System for customizing visual field (VF) tests uses a machine learning model (15) trained on retina images (12A, 12C, 12D), including optical coherence tomography (OCT), optical coherence tomography angiography (OCTA), fundus, and/or fluorescein angiography images. In operation, in preparation for administering a specific VF test (13) to a patient, a retina image of the patient is submitted to the present machine model, which responds by synthesizing a VF prediction for the patient. The synthesized VF may be used to optimize the specific VF test prior to administering it to the patient.Type: ApplicationFiled: September 4, 2020Publication date: December 22, 2022Inventors: Gary LEE, John G. FLANAGAN
-
Patent number: 11439615Abstract: Methods and compositions for inhibiting or preventing neurodegeneration, specifically hippocampal, cortical, and/or retinal ganglion cell neurons (RGC), and degeneration and/or cell loss or treating related disorders and diseases comprising administering to a subject an effective amount of one or more lipoxin compounds and/or lipoxin analogues such that degeneration and/or cell loss of neurons is inhibited or prevented.Type: GrantFiled: March 9, 2018Date of Patent: September 13, 2022Assignees: University Health Network, The Regents of the University of CaliforniaInventors: Jeremy M. Sivak, Izhar Livne-Bar, John G. Flanagan, Karsten Gronert, Jessica Wei
-
Publication number: 20210275484Abstract: Methods and compositions for inhibiting or preventing neurodegeneration, specifically hippocampal, cortical, and/or retinal ganglion cell neurons (RGC), and degeneration and/or cell loss or treating related disorders and diseases comprising administering to a subject an effective amount of one or more lipoxin compounds and/or lipoxin analogues such that degeneration and/or cell loss of neurons is inhibited or prevented.Type: ApplicationFiled: March 9, 2018Publication date: September 9, 2021Inventors: Jeremy M. Sivak, Izhar Livne-Bar, John G. Flanagan, Karsten Gronert, Jessica Wei
-
Patent number: 9744188Abstract: Disclosed herein are methods of inducing neuronal outgrowth of a neuron. The methods comprise contacting the neuron with an agent that binds receptor protein tyrosine phosphatase ? (RPTP?), to thereby induce neuronal outgrowth of the neuron. The agent may induces clustering of RPTP? and/or inhibit binding of chondroitin sulfate proteoglycan (CSPG) to RPTP?. Examples of suitable agents are heparan sulfate proteoglycan, heparan sulfate, heparan sulfate oligosaccharides, or heparin oligosaccharides. Additional agents are also disclosed. The neuron can be a CNS neuron or peripheral neuron. Also disclosed herein are methods of treating neuronal injury in a subject comprising, administering to the subject an agent that binds RPTP?. Administration may be to a site of neuronal injury, to thereby induce neuronal outgrowth at the site of neuronal injury.Type: GrantFiled: February 17, 2012Date of Patent: August 29, 2017Assignees: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORDInventors: John G. Flanagan, Yingjie Shen, Edith Yvonne Jones, Alexandru Radu Aricescu, Charlotte Hannah Coles
-
Publication number: 20140045762Abstract: Disclosed herein are methods of inducing neuronal outgrowth of a neuron. The methods comprise contacting the neuron with an agent that binds receptor protein tyrosine phosphatase ? (RPTP?), to thereby induce neuronal outgrowth of the neuron. The agent may induces clustering of RPTP? and/or inhibit binding of chondroitin sulfate proteoglycan (CSPG) to RPTP?. Examples of suitable agents are heparan sulfate proteoglycan, heparan sulfate, heparan sulfate oligosaccharides, or heparin oligosaccharides. Additional agents are also disclosed. The neuron can be a CNS neuron or peripheral neuron. Also disclosed herein are methods of treating neuronal injury in a subject comprising, administering to the subject an agent that binds RPTP?. Administration may be to a site of neuronal injury, to thereby induce neuronal outgrowth at the site of neuronal injury.Type: ApplicationFiled: February 17, 2012Publication date: February 13, 2014Applicants: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY FO OXFORD, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: John G. Flanagan, Yingjie Shen, Edith Yvonne Jones, Alexandru Radu Aricescu, Charlotte Hannah Bonn
-
Publication number: 20120231014Abstract: A method of promoting neural cell regeneration is carried out by contacting a neural cell with a compound that inhibits the binding of a chondroitin sulfate proteoglycan (CSPG) to a cellular (e.g., trans-membrane) PTP? protein. The neural cell is associated with an injury or neurodegenerative condition.Type: ApplicationFiled: August 18, 2010Publication date: September 13, 2012Applicants: CASE WESTERN RESERVE UNIVERSITY, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: John G. Flanagan, Alan Peter Tenney, Yingjie Shen, Jerry Silver
-
Patent number: 6919313Abstract: Transmembrane B ephrins and their Eph receptors signal hi-directionally. The presently claimed invention describes a cytoplasmic protein, designated PDZ-RGS3, which binds B ephrins through a PDZ domain, and has a regulator of heterotrimeric G protein signaling (RGS) domain. PDZ-RGS3 mediates signaling from the ephrin-B cytoplasmic tail. SDF-1, a chemokine with a G protein coupled receptor, or BDNF, act as chemoattractants for cerebellar granule cells, with SDF-1 action being selectively inhibited by soluble EphB receptor. The claimed invention reveals a pathway that links reverse signaling to cellular guidance, uncovers a novel mode of control for G proteins, and demonstrates a mechanism for selective regulation of responsiveness to neuronal guidance cues.Type: GrantFiled: April 1, 2002Date of Patent: July 19, 2005Assignee: President & Fellows of Harvard CollegeInventors: John G. Flanagan, Qiang Lu, Edna E. Sun
-
Patent number: 6777536Abstract: The present invention relates to the discovery of a novel EPH receptor ligand, referred to hereinafter as “Elf-1”, which protein has apparently broad involvement in the formation and maintenance of ordered spatial arrangements of differentiated tissues in vertebrates, and can be used to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: GrantFiled: February 27, 1995Date of Patent: August 17, 2004Assignee: President and Fellows of Harvard CollegeInventors: John G. Flanagan, Hwai-Jong Cheng
-
Publication number: 20030022202Abstract: Transmembrane B ephrins and their Eph receptors signal bi-directionally. The presently claimed invention describes a cytoplasmic protein, designated PDZ-RGS3, which binds B ephrins through a PDZ domain, and has a regulator of heterotrimeric G protein signaling (RGS) domain. PDZ-RGS3 mediates signaling from the ephrin-B cytoplasmic tail. SDF-1, a chemokine with a G protein coupled receptor, or BDNF, act as chemoattractants for cerebellar granule cells, with SDF-1 action being selectively inhibited by soluble EphB receptor. The claimed invention reveals a pathway that links reverse signaling to cellular guidance, uncovers a novel mode of control for G proteins, and demonstrates a mechanism for selective regulation of responsiveness to neuronal guidance cues.Type: ApplicationFiled: April 1, 2002Publication date: January 30, 2003Inventors: John G. Flanagan, Qiang Lu, Edna E. Sun
-
Publication number: 20020156239Abstract: The present invention relates to the discovery of a novel EPH receptor ligand, referred to hereinafter as “Elf-1”, which protein has apparently broad involvement in the formation and maintenance of ordered spatial arrangements of differentiated tissues in vertebrates, and can be used to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: ApplicationFiled: July 31, 2001Publication date: October 24, 2002Inventors: John G. Flanagan, Hwai-Jong Cheng
-
Patent number: 6399326Abstract: We describe here a new class of protein tyrosine phosphatases (PTP), called “PTP-NP” (for neural and pancreatic) receptors. The sequence of an exemplary PTP-NP gene (SEQ ID No. 1) indicates it encodes a receptor type PTP (SEQ ID No. 2) with a single tyrosine phosphatase domain. Comparison of PTP-NP with the other known PTPs reveals a cysteine-conserved motif in the extracellular domain and, together with their homology in the phosphatase domain, this defines a new subclass of receptor type PTPs.Type: GrantFiled: June 27, 1997Date of Patent: June 4, 2002Assignee: President and Fellows of Harvard CollegeInventors: Ming-Ko Chiang, John G. Flanagan
-
Patent number: 6268476Abstract: The present invention relates to the discovery of a novel EPH receptor ligand, referred to hereinafter as “Elf-1”, which protein has apparently broad involvement in the formation and maintenance of ordered spatial arrangements of differentiated tissues in vertebrates, and can be used to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: GrantFiled: September 19, 1994Date of Patent: July 31, 2001Assignee: President and Fellows of Harvard CollegeInventors: John G. Flanagan, Hwai-Jong Cheng
-
Patent number: 5801000Abstract: Disclosed is a method of isolating a ligand from a sample, the method including: providing a hybrid molecule including the receptor for the ligand covalently bonded to the first member of a specific binding pair; contacting sample with the hybrid molecule to form an affinity complex between the ligand and the hybrid molecule; and isolating the affinity complex using the second member of the specific binding pair. Also disclosed is a c-kit ligand, nucleic acid encoding such a ligand, and recombinant cells containing such nucleic acid. The c-kit ligand may be used to stimulate hematopoietic cell growth.Type: GrantFiled: February 29, 1996Date of Patent: September 1, 1998Assignee: President and Fellows of Harvard CollegeInventors: Philip Leder, John G. Flanagan
-
Patent number: 5795734Abstract: The present invention relates to the discovery of a novel EPH receptor ligand, referred to hereinafter as "Elf-1", which protein has apparently broad involvement in the formation and maintenance of ordered spatial arrangements of differentiated tissues in vertebrates, and can be used to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: GrantFiled: May 31, 1995Date of Patent: August 18, 1998Assignee: President and Fellows of Harvard CollegeInventors: John G. Flanagan, Hwai-Jong Cheng
-
Patent number: 5789182Abstract: A homogeneous population of cells having on average (1) a number of cell surface low-affinity heparin-binding growth factor (HBGF) sites per cell less than 20% of the number of such binding sites found on wild-type CHO-K1 cells (ATCC Accession No. CCL61), and at least three times the number of cell surface high-affinity HBGF receptors per cell found on such CHO-K1 cells; and an assay system utilizing such cells.Type: GrantFiled: December 14, 1993Date of Patent: August 4, 1998Assignees: The Children's Medical Center Corporation, President and Fellows of Harvard CollegeInventors: Avner Yayon, David M. Ornitz, Michael Klagsbrun, Philip Leder, John G. Flanagan
-
Patent number: 5554499Abstract: Disclosed is a method of isolating a ligand from a sample, the method including: providing a hybrid molecule including the receptor for the ligand covalently bonded to the first member of a specific binding pair; contacting sample with the hybrid molecule to form an affinity complex between the ligand and the hybrid molecule; and isolating the affinity complex using the second member of the specific binding pair. Also disclosed is a c-kit ligand, nucleic acid encoding such a ligand, and recombinant cells containing such nucleic acid. The c-kit ligand may be used to stimulate hematopoietic cell growth.Type: GrantFiled: September 14, 1994Date of Patent: September 10, 1996Assignee: President and Fellows of Harvard CollegeInventors: Philip Leder, John G. Flanagan